AR050245A1 - 3-piperidinilisocroman-5-oles como agonistas de dopamina y composicion farmaceutica que lo contiene - Google Patents

3-piperidinilisocroman-5-oles como agonistas de dopamina y composicion farmaceutica que lo contiene

Info

Publication number
AR050245A1
AR050245A1 ARP050101668A ARP050101668A AR050245A1 AR 050245 A1 AR050245 A1 AR 050245A1 AR P050101668 A ARP050101668 A AR P050101668A AR P050101668 A ARP050101668 A AR P050101668A AR 050245 A1 AR050245 A1 AR 050245A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
hydrogen
phenyl
benzyl
Prior art date
Application number
ARP050101668A
Other languages
English (en)
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of AR050245A1 publication Critical patent/AR050245A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Estos compuestos son utiles para tratar trastornos neurologicos relacionados con la dopamina, seleccionados del grupo que consiste en trastornos neurologicos, psicologicos, cardiovasculares, cognitivos o de atencion, abuso de sustancias y comportamiento adictivo, o una de sus combinaciones, que comprende administrar a un paciente que necesite dicho tratamiento, una cantidad terapéuticamente eficaz de compuestos de formula 1 Reivindicacion 1: Un compuesto de acuerdo con la formula 1 en la que R1 se selecciona del grupo que consiste en hidrogeno, fenoxicarbonilo, alcoxi(C1-6)-carbonilo, benciloxicarbonilo, naftiloxicarbonilo, fenilcarbamoilo, fenilcarbamoil-alquilo (C1-6), bifenilcarbamoilo, fenil-alquil(C1-6)-carbamoilo, N- fenil-N-alquil(C1-6)-carbamoilo, alquil(C1-6)- y dialquil(C1-6)-carbamoilo, alquenil(C2-6)- y dialquenil(C2-6)-carbamoilo, difenilcarbamoilo, heteroarilcarbamoil-alquilo(C1-6), fenilcarbonilo, bifenilcarbonilo, alquil(C1-6)-carbonilo, morfolinilcarbonilo, piperidinilcarbonilo, pirrolidinilcarbonilo, fenotiazinilcarbonilo, fenilsulfonilo, difenilsulfonilo, naftilsulfonilo, alquilsulfonilo C1-10, naftil-alquil(C1-6)- sulfonilo, perfluoralquilsulfonilo C1-6, difenil-alquil(C1-6)- sulfonilo, bencenosulfonilo, dialquil(C1-6)-aminosulfonilo, difenil-alquilo(C1-6), bencilo, fenil-alquilo(C2-6), naftil-alquilo(C1-6); cicloalquil(C3-6)-alquilo(C1-6), fenil-alquienilo(C1-6), heteroaril-alquilo(C1-6), alfa-carboxibencilo, fenilcarbonilalquilo(C1-6), hidroxialquilo(C1-6), bifenil-alquilo(C1-6), alquilo C1-6, fenoxifenil-alquilo(C1-6), fenilurea-alquilo,indanilo, en los que el bencilo y fenilo están opcionalmente sustituidos con uno o dos sustituyentes independientemente seleccionado cada uno del grupo que consiste en alquilo C1-6, perfluoroalquilo C1-6, halogeno, hidroxi, alcoxi C1-6 y nitro, y en los que heteroarilo es tiofenilo, benzotiofenilo, furanilo, benzofuranilo, tetrahidroquinolilo, tetrahidroisoquinolilo, indolilo, imidazolilo, bencimidazolilo, piridinilo, isotiazolilo, bencisotiazolilo, isoxazolilo, bencisoxazolilo, isoquinolilo o quinolilo, en los que el heteroarilo está opcionalmente sustituido con uno o dos sustituyentes independientemente seleccionados del grupo de alquilo C1-6, halogeno, hidroxi, bencilo y alcoxi C1-6, formula 2, 3 4 y 5 en los que R es hidrogeno o bencilo, Y se selecciona del grupo que consiste en hidrogeno, alquilo C1-6, perfluoralquilo C1-6, halogeno, hidroxi, alcoxi C1-6 y nitro; R2 y R3 son iguales o diferentes y se seleccionan independientemente del grupo que consiste en hidrogeno, alquilo C1-6, alquil (C1-6)-carbonilo, formilo, alquenilo C2-6, cicloalquilo (C3-6)-alquilo(C1-6), y R2, R3 considerados juntos pueden formar un anillo de 2-5átomos de carbono; R4 se selecciona del grupo que consiste en hidrogeno, alquilo C1-4 y alquil(C1-6)-carbonilo; X se selecciona del grupo que consiste en hidrogeno y alquilo C1-6; y n es un numero entreo 1, 2 o 3; un esteroisomero o una de sus sales farmacéuticamente aceptable.
ARP050101668A 2004-04-29 2005-04-28 3-piperidinilisocroman-5-oles como agonistas de dopamina y composicion farmaceutica que lo contiene AR050245A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56655704P 2004-04-29 2004-04-29

Publications (1)

Publication Number Publication Date
AR050245A1 true AR050245A1 (es) 2006-10-11

Family

ID=34967397

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050101668A AR050245A1 (es) 2004-04-29 2005-04-28 3-piperidinilisocroman-5-oles como agonistas de dopamina y composicion farmaceutica que lo contiene

Country Status (11)

Country Link
US (1) US7919508B2 (es)
EP (1) EP1749001B1 (es)
JP (1) JP4685861B2 (es)
AR (1) AR050245A1 (es)
AT (1) ATE459618T1 (es)
DE (1) DE602005019719D1 (es)
DK (1) DK1749001T3 (es)
ES (1) ES2342083T3 (es)
PT (1) PT1749001E (es)
TW (1) TW200607802A (es)
WO (1) WO2005111025A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6458957B2 (ja) * 2013-10-22 2019-01-30 チエシ ファルマスティスィ エス．ピー．エー． Ｐｄｅ４阻害剤の製造方法
WO2015166366A1 (en) * 2014-04-28 2015-11-05 Pfizer Inc. Heterocyclic compounds and their use as dopamine d1 ligands
LT3204359T (lt) * 2014-10-08 2020-10-12 UCB Biopharma SRL Tetrahidroizochinolino dariniai
MX2019000982A (es) * 2016-07-29 2019-07-04 Sunovion Pharmaceuticals Inc Compuestos y composiciones y usos de los mismos.
CN110088107B (zh) 2016-07-29 2023-04-14 赛诺维信制药公司 化合物、组合物及其用途
JP7471818B2 (ja) 2016-08-18 2024-04-22 ヴィダック ファーマ リミテッド ピペラジン誘導体、医薬組成物、及びその使用方法
WO2019028165A1 (en) * 2017-08-02 2019-02-07 Sunovion Pharmaceuticals Inc. ISOCHROMAN COMPOUNDS AND USES THEREOF
CN111196781B (zh) * 2018-11-16 2023-07-28 湖南中南制药有限责任公司 一种改进的制备五氟利多的方法
KR20210139376A (ko) 2019-03-14 2021-11-22 선오비온 파마슈티컬스 인코포레이티드 이소크로마닐 화합물의 염, 및 이의 결정성 형태, 제조방법, 치료 용도 및 약제학적 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994486A (en) * 1989-05-31 1991-02-19 Abbott Laboratories Dopaminergic compounds
US4963568A (en) * 1989-05-31 1990-10-16 Abbott Laboratories Dopamine agonists
NZ336719A (en) * 1997-02-07 2000-10-27 Hoechst Marion Roussel Inc 4-piperidinyl-1H-2-benzopyran derivatives useful as antipsychotic and process for preparation agents
US6004982A (en) * 1997-09-15 1999-12-21 Hoechst Marion Roussel, Inc. 4-piperidinyl) H-2-benzopyran derivatives useful as antipsychotic agents

Also Published As

Publication number Publication date
JP4685861B2 (ja) 2011-05-18
DK1749001T3 (da) 2010-06-28
PT1749001E (pt) 2010-05-31
EP1749001B1 (en) 2010-03-03
DE602005019719D1 (de) 2010-04-15
US7919508B2 (en) 2011-04-05
EP1749001A1 (en) 2007-02-07
US20070099955A1 (en) 2007-05-03
ATE459618T1 (de) 2010-03-15
WO2005111025A1 (en) 2005-11-24
ES2342083T3 (es) 2010-07-01
TW200607802A (en) 2006-03-01
JP2007535548A (ja) 2007-12-06

Similar Documents

Publication Publication Date Title
AR050245A1 (es) 3-piperidinilisocroman-5-oles como agonistas de dopamina y composicion farmaceutica que lo contiene
PE20230249A1 (es) Compuestos de heteroarilo biciclicos y usos de estos
CL2019001988A1 (es) Compuestos químicos como inhibidores de actividad interleuquina-2.
PE20191496A1 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
PE20221457A1 (es) Degradadores de moleculas pequenas de helios y procedimientos de uso
PE20181093A1 (es) Compuestos heterociclicos y usos de los mismos
GT200600165A (es) Derivados dihidrobenzofuranos y usos de los mismos
AR054280A1 (es) Derivados de carboxamidas y su empleo en procedimientos de lucha contra enfermedades de plantas y contra hongos nocivos
AR068512A1 (es) Derivados de 4-aril-1h-piridin-2-onas disustituidas, composiciones farmaceuticas que las contienen y usos de las mismas para tratar o prevenir trastornos del sistema nervioso central
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
AR054612A1 (es) Derivados de espiroquetas y composiciones farmaceuticas para su utilizacion como agente terapeutico para diabetes
GT200500225A (es) Compuestos de aminoheteroarilo enantiomericamente puros como inhibidores de proteina quinasa
CL2007002450A1 (es) Forma polimorfica i del enantiomero levogiro o dextrogiro de modafinilo; su procedimiento de preparacion; y composicion farmaceutica que los comprende (divisional solicitud 2693-03).
EA200970928A1 (ru) Антагонисты рецептора гонадотропин-рилизин-фактора и способы их применения
AR054786A1 (es) (6-fluor-benzol(1,3) dioxolil)-morfolin-4-il-metanomas, moduladoras del receptor cb1
AR111315A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CO6321273A2 (es) N-fenil -y - lactamas subtituidas las cuales son agonistas ep2 para ser usados como agentes terapeuticos para el tratamiento de glaucoma, sindrome del intestino irritable y calvicie
EA201390717A1 (ru) 3-(аминоарил)пиридиновые соединения
AR104555A1 (es) SULFONAS TRICÍCLICAS COMO MODULARES DE RORg
CL2007001711A1 (es) Compuestos derivados de pirazolopiridina sustituida;composicion farmaceutica que los comprende;metodo de preparacion de los compuestos ,compuestos intermediarios;y su uso en el tratamiento de enfermedades,tales como tumores,artritis reumatoide,enfermedades del crecimiento vascular desregulado, entre otras.
AR104331A1 (es) Derivados de tetrazol
PE20201280A1 (es) Amidas de imidazopiridina sustituidas y su uso
AR061973A1 (es) Compuesto de 2-arilindol sustituido en la posicion 5, composicion farmaceutica que lo comprende, compuestos intermedios y procedimiento para la preparacion de los mismos
AR061583A1 (es) Acidos 6-(bencilo sustituido con heterociclil)-4-oxiquinolin carboxilicos, inhibidores de vih-integrasas, composiciones farmaceuticas que los contienen y usos como agentes anti-vih.
AR045155A1 (es) Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal